Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16005286 | 1.00 | MEN1 (0.48) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL16005406 | 1.00 | MEN1 (0.48) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL14801943 | 1.00 | MEN1 (0.48) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL16005383 | 1.00 | MEN1 (0.48) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL28455706 | 1.00 | MEN1 (0.48) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL16005645 | 1.00 | MEN1 (0.48) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL2955801 | 1.00 | MEN1 (0.48) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL16005391 | 1.00 | MEN1 (0.48) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL515809 | 0.96 | — | — | |
| SCHEMBL4887517 | 0.80 | MEN1 (0.41) | MEN1KMT2ATSHRMAPK1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2774915-A1 | New derivatives of resveratrol | Mattarei, Andrea (IT) | 2014-09-10 | — | — | EP | claimed |
| US-20240293570-A1 | HIGHLY STABLE TARGETED LINKER-DRUG CONJUGATE | CHENGDU SCIMOUNT PHARMATECH CO., LTD. (CN) | 2024-09-05 | — | — | US | disclosed |
| EP-4420682-A1 | HIGHLY-STABLE TARGETED LINKER-DRUG CONJUGATE | Chengdu Scimount Pharmatech Co., Ltd. (CN) | 2024-08-28 | — | — | EP | disclosed |
| CN-115957338-A | High-stability targeting joint-drug conjugate | 成都科岭源医药技术有限公司 | 2023-04-14 | — | — | CN | disclosed |
| EP-2774915-A1 | New derivatives of resveratrol | Mattarei, Andrea (IT) | 2014-09-10 | — | — | EP | disclosed |
| US-6770267-B2 | Methods of treating periodontal disease | SMITHKLINE BEECHAM CORPORATION | 2004-08-03 | — | — | US | disclosed |
| US-20040034020-A1 | Methods of treating periodontal disease | DALUGE SUSAN MARY (US) | 2004-02-19 | — | — | US | disclosed |
| EP-1104422-B1 | PHENYL XANTHINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2004-02-18 | — | — | EP | disclosed |
| US-6608069-B1 | Treating AIDS-related diarrhea or infectious diarrhea, tissue damage or dermatitis associated with leukocyte infiltration into tissue, asthma, inflammatory bowel condition, eczema, or psoriasis | SMITHKLINE BEECHAM CORPORATION | 2003-08-19 | — | — | US | disclosed |
| US-20030032804-A1 | Methods of treating periodontal disease | SMITHKLINE BEECHAM CORPORATION | 2003-02-13 | — | — | US | disclosed |
| EP-1104422-A1 | PHENYL XANTHINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000009507-A1 | PHENYL YANTHINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034020-A1 | Methods of treating periodontal disease | MMP8, LPO, PTGES3 | MEN1 4696/4885KMT2A 3106/4885TSHR 3131/4885 |
| US-20030032804-A1 | Methods of treating periodontal disease | HPGDS, SELP, ALPI | MEN1 4795/4885KMT2A 4676/4885TSHR 3123/4885 |
| US-20240293570-A1 | HIGHLY STABLE TARGETED LINKER-DRUG CONJUGATE | DARS1, FCGR2A, CD44 | MEN1 480/4885KMT2A 2322/4885TSHR 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.